Bajaj Healthcare Limited: Financial Performance

Key Takeaways from the Income Statement: Steady Revenue Growth: Revenue from operations grew by 18.9% YoY for the quarter (reaching Rs. 17,590.16 Lakhs compared to Rs. 14,791.49 Lakhs in Q2 FY26). For the half-year period, revenues expanded by 15.1% YoY to Rs. 34,153.33 Lakhs. ** Profitability Expansion: Profit after tax from continuing operations increased to Rs. 1,437.98 Lakhs for the quarter, marking a 15.5% YoY improvement. **Discontinued Operations: Losses from discontinued units narrowed significantly to Rs. 28.58 Lakhs for the quarter compared to a loss of Rs. 133.94 Lakhs in the corresponding quarter of the previous year. Balance Sheet & Capital Structure Highlights : Total Assets: Stood at Rs. 98,114.81 Lakhs as of September 30, 2026, up from Rs. 92,321.72 Lakhs as of March 31, 2026. Net Worth (Equity): Total equity strengthened to Rs. 55,716.11 Lakhs (Share Capital of Rs. 1,683.26 Lakhs + Other Equity of Rs. 54,032.85 Lakhs). Borrowings: Non-current borrowings stood at Rs. 7,038.06 Lakhs, while current borrowings were recorded at Rs. 19,713.71 Lakhs. Acquisition of Genrx Pharmaceuticals Private Limited : Initially acquired in April 2025 on a going concern basis for Rs. 1,085.00 Lakhs, the formal subsidiary integration was pending NCLT approvals. Major Update: On October 13, 2026, the company received an order from the Hon’ble NCLT approving the acquisition. Consequently, Genrx Pharmaceuticals Private Limited will become a wholly-owned subsidiary of Bajaj Healthcare Limited upon finalization of legal and procedural formalities.